NCT03718533View on ClinicalTrials.gov

Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 17, 2018

Primary Completion Date

November 3, 2020

Study Completion Date

November 3, 2020

Conditions
Poor Graft Function
Interventions
DRUG

Eltrombopag

Eltrombopag was provided as 50 mg or 25 mg film-coated tablets for oral use administration

Trial Locations (7)

20080

Novartis Investigative Site, Donostia / San Sebastian

29010

Novartis Investigative Site, Málaga

36212

Novartis Investigative Site, Vigo

37007

Novartis Investigative Site, Salamanca

46010

Novartis Investigative Site, Valencia

07120

Novartis Investigative Site, Palma de Mallorca

08041

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY